Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US09073M1045
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000C15114
TECH
Bio-Techne Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Bio-Techne Corp
ISIN
US09073M1045
TICKER
TECH
MIC
XNAS
REUTERS
TECH.OQ
BLOOMBERG
TECH US
Di., 15.07.2025       Bio-Techne
US09073M1045

Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership sig...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 15.07.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for c...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 14.07.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 24.06.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to s...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 10.06.2025       Bio-Techne
US09073M1045

ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing i...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 29.05.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: William Blair 45th Annual Growth Stock ConferenceJune 3, 20252:40 PM CDT Jefferies Global Healthcare ConferenceJune 4, 20253:45 PM EDT Goldman Sachs 46th Annual Global Healthcare ConferenceJun...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 14.05.2025       Bio-Techne
US09073M1045

ST. PAUL, Minn., May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA). The funding to...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 12.05.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, May 12, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13th – 17th at the New Orleans Ernest N. Morial Con...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 08.05.2025       Bio-Techne
US09073M1045

Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing.The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficienc...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 08.05.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Te...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 07.05.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be conside...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 06.05.2025       Bio-Techne
US09073M1045

ST. PAUL, Minn., May 6, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf, Bio-Techne Corporation and CellReady, today announced that A2 Biotherapeutics, Inc. ("A2") has been awarded a $300,000 G-Rex® Grant.  A2's G-Rex® Grant will enable expeditious process development and qualification of a G-Rex-based production system and wil...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 29.04.2025       Bio-Techne
US09073M1045

ST. PAUL, Minn., April 29, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been awarded a $200,000 G-Rex® Grant. March Biosciences' G-Rex® Grant will be used to advance the manufacturing of their lead asset, MB-105, a novel investiga...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 24.04.2025       Bio-Techne
US09073M1045

New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues MINNEAPOLIS, April 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest advancement in spatial...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 23.04.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, April 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL. Bio-Techne's booths will featu...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 15.04.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, April 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 7, 2025, at 8:00 a.m. CDT to review its third quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time:            8:00 a.m. CDT Date: ...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 02.04.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automatio...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 26.03.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy. The new Customer Experience Centre is schedu...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 24.03.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be hig...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 03.03.2025       Bio-Techne
US09073M1045

AmplideX® Nanopore Carrier Plus Kit uses nanopore sequencing to resolve high-prevalence genes. MINNEAPOLIS and OXFORD, England, March 3, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore Technologies to launch the AmplideX® Nanopore Carrier Plus Kit, a...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 20.02.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deli...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 18.02.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based th...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 12.02.2025       Bio-Techne
US09073M1045

Das Instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 13.02.2025 und ex Dividende/Zinsen am 14.02.2025 The instrument TE1 US09073M1045 BIO-TECHNE CORP. DL-,01 EQUITY has its pre-dividend/interest day on 13.02.2025 and its ex-dividend/interest day on 14.02.2025...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 05.02.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends w...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 05.02.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024. Second Quarter FY2025 Highlights Second quarter organic revenue increased by 9% (9% reported) to $297.0 million.GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Del...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 04.02.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancell...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 21.01.2025       Bio-Techne
US09073M1045

ST. PAUL, Minn., Jan. 21, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been awarded a $300,000 G-Rex® Grant. The G-Rex® Grant will support expeditious process development and commercial readiness of BCB-276, BrainChild Bio's lead aut...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 21.01.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025, at 8:00 a.m. CST to review its second quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: Februar...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 08.01.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 08.01.2025       Bio-Techne
US09073M1045

ST. PAUL, Minn., Jan. 8, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, today announced that Seattle Children's Therapeutics, a division of the Seattle Children's Research Institute has been awarded a $125,000 G-Rex Grant.  The G-Rex Grant will integrate state-of-the-art advancements i...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 07.01.2025       Bio-Techne
US09073M1045

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Fr., 20.12.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page o...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 19.12.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies p...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 18.12.2024       Bio-Techne
US09073M1045

ST. PAUL, Minn., Dec. 18, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell therap...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 12.12.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 10.12.2024       Bio-Techne
US09073M1045

Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium MINNEAPOLIS, Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 27.11.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 25.11.2024       Bio-Techne
US09073M1045

WEST SACRAMENTO, Calif., Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 20.11.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Tech...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 18.11.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 14.11.2024       Bio-Techne
US09073M1045

Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 11.11.2024       Bio-Techne
US09073M1045

R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C.  MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vit...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mo., 11.11.2024       Bio-Techne
US09073M1045

R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Contro...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Fr., 08.11.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare ConferenceNovember 12, 20249:30 AM PST Stifel 2024 Healthcare ConferenceNovember 19, 20248:00 AM EST Stephens NASH 2024 ConferenceNovember 20, 202411:00 AM CST A live web...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Do., 07.11.2024       Bio-Techne
US09073M1045

ST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation and CellReady, has awarded G-Rex Grants totaling $475,000 to three leading investigators at the Baylor College of Medicine's (BCM) Center for Cell and Gene Therapy Institute (CAGT). Dr. Ann Leen, a Professor in the...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 06.11.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Di., 05.11.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne's Lunaphore branded end-to-end spatial biology offering, including its complete range of instruments (COMET) and kits that offer high-value solutions for t...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 30.10.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024. The quarterly dividend will be  payable November 22, 2024, to all common shareholders of record on November 11, 2024. Future cash dividend...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink
Mi., 30.10.2024       Bio-Techne
US09073M1045

MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million. GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Deli...
Zur Nachricht
Bio-Techne
Charts & Research Termsheets Terminal
Permalink